Live Chat

CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 74% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.

Close

Handelen Gilead GILD

Gilead live grafieken

instrument_fundamentals

Weekly Search
Weekly
Daily
Datum Sluit Verandering % verandering Openen Piek Bodem

Nieuws

Info

Spread

0.57

Spread (%)

0.6213 %

Hefboom

1:5

Dagrente kopen

-0.0597 %

Dagrente verkopen

-0.0292 %

Valuta

USD

Openingstijden

Markt gesloten

Vrijdag

14:31 - 20:59

Maandag

14:31-20:59

Dinsdag

14:31-20:59

Woensdag

14:31-20:59

Donderdag

14:31-20:59

instr__analysis_statistics

Openen

---

Vorige Sluiten

---

52-weekse hoog/laag

--- – ---

Beurswaarde

117585453056

Uitstaande aandelen

1246000000

Datum winstcijfer (volgende)

2013-01-28

Div. rend.

2024-09-27

Ex-dividenddatum

2024-12-13

Jaarlijks verwachte dividendpercentage

3.08

Jaarlijks verwachte dividendrendement

0.0326

Winst per aandeel

0.09

Meer informatie over dit instrument

Gilead Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Gerelateerde instrumenten

Activa
Verkoop
Koop
% verandering
Gerelateerde instrumenten

Laatste marktnieuws

Blijf op de hoogte van het laatste financiële nieuws uit de hele wereld.

Donderdag, 14 November 2024

Dogecoin surges after Elon Musk issues crypto endorsement

Nvidia Blackwell AI Chips

Donderdag, 14 November 2024

Week ahead: Tech rally hinges on Nvidia earnings

Dogecoin surges

Woensdag, 13 November 2024

Dogecoin surges as Trump unveils new government efficiency initiative with Musk andRamaswamy

Woensdag, 13 November 2024

Japanese Yen to USD: Yen drops to fresh multi-month low against USD

Woensdag, 13 November 2024

Asia markets today: Nikkei 225 up 0.18%, Hang Seng Index falls by 197 points

Dinsdag, 12 November 2024

UK stock market news: Helium One share price trading 16.1% higher

Dinsdag, 12 November 2024

Leveraged ETF to package Warren Buffett's Berkshire Hathaway B stock

Dinsdag, 12 November 2024

Dogecoin surges 20% after Department of Government Efficiency announcement

Trustpilot
Live Chat